IN THE SPECIFICATION:

Please revise the specification as follows:

1) Please amend paragraph 2 on page 16, line 6 from the top of the page as shown by the following marked up version of the revised paragraph:

In one embodiment, an 18-base phosphorothioate bcl-2 antisense oligomer of the sequence 5'-TCTCCCAGCGTGCGCCAT-3' (SEQ ID NO:17), which is complimentary to the first six codons of the bcl-2 mRNA and hybridizes to the respective target RNA bases, is administered for a short treatment cycle, defined as less than two weeks.

2) Please amend the first full paragraph, page 31, line 4 from the top of the page as shown by the following marked up version of the revised paragraph:

BCL-2 antisense oligomer (sequence 5'TCTCCCAGCGTGCGCCAT-3' (SEQ ID NO:17)) was administered as a continuous intravenous infusion (CIV) for 14 days by an ambulatory infusion pump (Sims Deltec Inc., St. Paul, MN, USA) through a central venous line. Using a separate peripheral intravenous line, DTIC was administered at doses of 200 mg/m^2/day given by one hour infusions for 5 days on days 5 though 9 of the 14-day BCL-2 antisense oligomer therapy. Treatment cycles were repeated monthly. Dose escalation was started at 0.6 mg/kg/day and continued with 1.3, 1.7, 2.1, 3.1, 4.1, 5.3 and 6.5 mg/kg/day of BCL-2 ASO. Once safety was established in a cohort of at least 3 patients at a given dose level, new patient cohorts were entered at the next higher dose level (Waters et al., 2000, J. Clin. Oncol.18(9):1812-23). Repeat 28 day cycles and intra-patient dose escalation were permitted in stable or responding patients after a two week observation period.

3) Please add the following paragraph to the first line of the specification as filed:

This application claims the benefit of United States Patent Application Serial No. 60/227,970, filed August 25, 2000 and United States Patent Application Serial No. 60/237,009, filed September 29, 2000.